logo
Share SHARE
FONT-SIZE Plus   Neg

AstraZeneca Advances MedImmune's Benralizumab To Phase III In Severe Asthma

AstraZeneca (AZN.L,AZN) said it has begun the Phase III Windward programme for benralizumab, a potential treatment for severe uncontrolled asthma developed by MedImmune, the company's global biologics research and development arm. The aim of CALIMA, the first trial in the Windward programme, is to determine whether benralizumab reduces the number of exacerbations in patients with severe asthma that remains uncontrolled, despite receiving high doses of inhaled corticosteroids combined with a second controller like long-acting beta agonist.

Benralizumab is a monoclonal antibody binding to the interleukin-5 receptor, that depletes eosinophils, a type of white blood cell, which play a critical role in the cause and severity of asthma and asthma exacerbations. Emerging evidence demonstrates that for patients with elevated eosinophil counts, treatment with an IL-5 inhibitor in addition to guideline-based strategies may increase their asthma control and decrease the frequency of asthma attacks.

The CALIMA trial would evaluate the safety and effectiveness of benralizumab in actively reducing exacerbations in patients with uncontrolled asthma, and assess the benralizumab effect on lung function, asthma symptoms and other asthma control measures, as well as emergency room and hospitalisation rates due to asthma.

The efficacy and safety data from this trial supported the progression of benralizumab into our Phase III programme. These results are likely to be shared at a scientific conference in the first half of 2014. Benralizumab is in-licensed from BioWa, Inc., a subsidiary of Kyowa Hakko Kirin Co., Ltd.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Etihad Airway's Chief Executive Officer James Hogan will leave in the second half this year. Hogan has been with the Abu Dhabi based aviation group since 2006. Chief Financial Officer James Rigney also will depart from service. Seafood lovers must now be prepared to dole out more cash than before for salmon. The price of salmon has surged globally and is now at historic highs amid acute outbreaks of sea lice. According to data from the Nasdaq Salmon Index, the price of salmon has risen by more than 15 percent in the last three months. Health-food restaurant chain Freshii Inc. has increased the price range for its initial public offering in Canada. Freshii has raised the price range for its IPO to C$10 to C$11.50 per share from the prior range of C$8.50 to C$10.0 per share, BNN reported.
comments powered by Disqus
Follow RTT